Y-mAbs Therapeutics, Inc. $YMAB Stake Lifted by Acorn Capital Advisors LLC

Key Points

• Acorn Capital Advisors LLC increased its stake in Y-mAbs Therapeutics by 13.1%, making it the company's 3rd largest holding with 3,235,387 shares valued at approximately $14.33 million.
• Y-mAbs Therapeutics reported a quarterly earnings per share of ($0.07), surpassing analyst expectations and generating revenue of $19.52 million, higher than their anticipated $18.40 million.
• Several research firms have recently downgraded their ratings on Y-mAbs Therapeutics, with Oppenheimer shifting from "outperform" to "market perform" and setting a price target of $8.60.

Acorn Capital Advisors LLC grew its holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 13.1% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 3,235,387 shares of the company's stock after acquiring an additional 373,562 shares during the quarter. Y-mAbs Therapeutics comprises 9.3% of Acorn Capital Advisors LLC's investment portfolio, making the stock its 3rd biggest holding. Acorn Capital Advisors LLC owned about 7.14% of Y-mAbs Therapeutics worth $14,333,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in YMAB. Infinitum Asset Management LLC purchased a new position in shares of Y-mAbs Therapeutics in the 4th quarter valued at about $1,218,000. Paradigm Biocapital Advisors LP increased its holdings in shares of Y-mAbs Therapeutics by 3.7% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 4,236,346 shares of the company's stock valued at $33,171,000 after acquiring an additional 150,000 shares during the last quarter. AQR Capital Management LLC increased its holdings in shares of Y-mAbs Therapeutics by 869.3% in the 1st quarter. AQR Capital Management LLC now owns 164,788 shares of the company's stock valued at $730,000 after acquiring an additional 147,788 shares during the last quarter. Stonepine Capital Management LLC purchased a new position in shares of Y-mAbs Therapeutics in the 1st quarter valued at about $581,000. Finally, Nuveen LLC purchased a new position in shares of Y-mAbs Therapeutics in the 1st quarter valued at about $498,000. Hedge funds and other institutional investors own 70.85% of the company's stock.

Y-mAbs Therapeutics Stock Up 0.1%

NASDAQ:YMAB opened at $8.55 on Friday. The stock's 50 day moving average price is $6.05 and its 200 day moving average price is $5.20. The company has a market capitalization of $388.51 million, a PE ratio of -17.10 and a beta of 0.57. Y-mAbs Therapeutics, Inc. has a 52-week low of $3.55 and a 52-week high of $16.11.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last posted its quarterly earnings data on Friday, August 8th. The company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.20. Y-mAbs Therapeutics had a negative return on equity of 24.60% and a negative net margin of 26.03%.The company had revenue of $19.52 million during the quarter, compared to analysts' expectations of $18.40 million. As a group, sell-side analysts anticipate that Y-mAbs Therapeutics, Inc. will post -0.65 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on YMAB. Oppenheimer downgraded Y-mAbs Therapeutics from an "outperform" rating to a "market perform" rating in a report on Tuesday, August 5th. HC Wainwright reiterated a "neutral" rating and issued a $8.60 price objective (down previously from $11.00) on shares of Y-mAbs Therapeutics in a report on Wednesday, August 6th. Morgan Stanley set a $8.60 price target on Y-mAbs Therapeutics in a research note on Tuesday, August 5th. Jones Trading downgraded Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 5th. Finally, Cantor Fitzgerald set a $8.60 price target on Y-mAbs Therapeutics and gave the stock a "neutral" rating in a research note on Tuesday, August 5th. Eight equities research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Reduce" and an average price target of $9.62.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.

Want to see what other hedge funds are holding YMAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.